RRM2 and hepatocellular carcinoma: Next, we performed RNAseq of the RRM2- and RRM2B-manipulated HepG2 cells with or without cisplatin treatment to determine their transcriptomic changes in comparison to the PTWAYRRM2 and PTWAYRRM2B we previously identified in HB and HCC patient tumors (Fig. 2e).